ATAI Life Sciences NV
ATAI
View Detailed Chart
4.070USD
-0.120-2.86%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
978.58MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.86%
5 Days
+2.78%
1 Month
+8.53%
6 Months
+80.89%
Year to Date
+206.02%
1 Year
+217.97%
View Detailed Chart
TradingKey Stock Score of ATAI Life Sciences NV
Currency: USD Updated: 2025-12-26Key Insights
ATAI Life Sciences NV's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 120/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ATAI Life Sciences NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
11
analysts
Buy
Current Rating
12.000
Target Price
+169.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ATAI Life Sciences NV Highlights
StrengthsRisks
Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.19% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 308.00K.
Undervalued
The company’s latest PE is -4.92, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 45.07M shares, increasing 0.04% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 444.03K shares of this stock.
ATAI Life Sciences NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ATAI Life Sciences NV Info
Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
Ticker SymbolATAI
CompanyATAI Life Sciences NV
CEORao (Srinivas G)
Websitehttps://www.atai.com/
FAQs
What is the current price of ATAI Life Sciences NV (ATAI)?
The current price of ATAI Life Sciences NV (ATAI) is 4.070.
What is the symbol of ATAI Life Sciences NV?
The ticker symbol of ATAI Life Sciences NV is ATAI.
What is the 52-week high of ATAI Life Sciences NV?
The 52-week high of ATAI Life Sciences NV is 6.750.
What is the 52-week low of ATAI Life Sciences NV?
The 52-week low of ATAI Life Sciences NV is 1.150.
What is the market capitalization of ATAI Life Sciences NV?
The market capitalization of ATAI Life Sciences NV is 978.58M.
What is the net income of ATAI Life Sciences NV?
The net income of ATAI Life Sciences NV is -149.27M.
Is ATAI Life Sciences NV (ATAI) currently rated as Buy, Hold, or Sell?
According to analysts, ATAI Life Sciences NV (ATAI) has an overall rating of Buy, with a price target of 12.000.
What is the Earnings Per Share (EPS TTM) of ATAI Life Sciences NV (ATAI)?
The Earnings Per Share (EPS TTM) of ATAI Life Sciences NV (ATAI) is -0.827.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%
